Skip to Content
Merck
  • Antitumorigenic effect of interferon-β by inhibition of undifferentiated glioblastoma cells.

Antitumorigenic effect of interferon-β by inhibition of undifferentiated glioblastoma cells.

International journal of oncology (2015-09-24)
Shun Yamamuro, Emiko Sano, Yutaka Okamoto, Yushi Ochiai, Takashi Ohta, Akiyoshi Ogino, Atsushi Natsume, Toshihiko Wakabayashi, Takuya Ueda, Hiroyuki Hara, Tomohiro Nakayama, Atsuo Yoshino, Yoichi Katayama
ABSTRACT

Glioma stem-like cells (GSCs) are undifferentiated cells that are considered to be an origin of glioblastomas. Furthermore, they may contribute to treatment resistance and recurrence in glioblastomas. GSCs differentiate into differentiated glioma cells (non-glioma stem-like cells: non‑GSCs), and interconversion might occur between GSCs and non-GSCs. We investigated whether interferon-beta (IFN-β) could exert any efficacy towards GSCs or such interconversion processes. The neural stem cell marker CD133 and pluripotency marker Nanog in GSCs were analyzed to evaluate their differentiation levels. GSCs were considered to undergo differentiation into non-GSCs upon serum exposure, since the expression of CD133 and Nanog in the GSCs was negatively affected. Furthermore, the cells regained their undifferentiated features upon removal of the serum. However, we verified that IFN-β reduced cell proliferation and tumor sphere formation in GSCs, and induced suppression of the restoration of such undifferentiated features. In addition, we also confirmed that IFN-β suppressed the acquisition process of undifferentiated features in human malignant glioma cell lines. Our data thus suggest that IFN-β could be an effective agent not only through its cell growth inhibitory effect on GSCs but also as a means of targeting the interconversion between GSCs and non-GSCs, indicating the possibility of IFN-β being used to prevent treatment resistance and recurrence in glioblastomas, via the inhibition of undifferentiated features.